Related Experiment Video

Updated: Jun 3, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Empiric antifungal therapy in patients with febrile neutropenia

Jenna J Ferrara1, Conan MacDougall, Jason C Gallagher

  • 1Department of Pharmacy, University of Pittsburgh Medical Center, St. Margaret Hospital, Pittsburgh, Pennsylvania, USA.

Pharmacotherapy
|April 1, 2011
PubMed

Insights

Empiric antifungal therapy is crucial for neutropenic patients with febrile neutropenia due to difficult diagnosis and high mortality. Selecting the right antifungal agent requires considering institutional fungal infection epidemiology and patient-specific factors.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Hematology

Background:

  • Invasive fungal infections (IFIs) significantly increase morbidity and mortality in neutropenic patients.
  • Diagnostic challenges in neutropenic patients complicate timely pharmacotherapy decisions.
  • Empiric antifungal therapy is standard for febrile neutropenia unresponsive to antibiotics.

Purpose of the Study:

  • To review the evolution and considerations for empiric antifungal pharmacotherapy in neutropenic patients.
  • To highlight the challenges and factors influencing the selection of antifungal agents.

Main Methods:

  • Review of current antifungal agents including amphotericin B formulations, azoles, and echinocandins.
  • Analysis of evidence supporting their use in febrile neutropenia.
  • Consideration of limitations such as drug intolerance, interactions, and adverse events.

Main Results:

  • Numerous antifungal agents are now available for empiric therapy.
  • Evidence supports their use, but limitations persist.
  • Drug intolerance, interactions, adverse events, and variable activity against molds impact efficacy.

Conclusions:

  • Selection of empiric antifungal therapy requires careful consideration of institutional fungal infection epidemiology.
  • Patient-specific clinical circumstances are critical in choosing the appropriate antifungal drug.
  • Ongoing evolution of pharmacotherapy necessitates informed decision-making to optimize patient outcomes.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...